Juvenile dermatomyositis is the most common form of the juvenile idiopathic inflammatory myopathies characterised by muscle and skin inflammation, leading to symmetric proximal muscle weakness and cutaneous symptoms. It has a fluctuating course and varying prognosis. In a Bayesian framework, we develop a joint model for four longitudinal outcomes, which accounts for within individual variability as well as inter-individual variability. Correlations among the outcome variables are introduced through a subject-specific random effect. Moreover, we exploit an approach similar to a hurdle model to account for excess of a specific outcome in the response. Clinical markers and symptoms are used as covariates in a regression set-up. Data from an ongoing observational cohort study are available, providing information on 340 subjects, who contributed 2725 clinical visits. The model shows good performance and yields efficient estimations of model parameters, as well as accurate predictions of the disease activity parameters, corresponding well to observed clinical patterns over time. The posterior distribution of the by-subject random intercepts shows a substantial correlation between two of the outcome variables. A subset of clinical markers and symptoms are identified as associated with disease activity. These findings have the potential to influence clinical practice as they can be used to stratify patients according to their prognosis and guide treatment decisions, as well as contribute to on-going research about the most relevant outcome markers for patients affected by juvenile dermatomyositis.
Introduction
The juvenile idiopathic inflammatory myopathies (IIM) are a group of heterogeneous chronic diseases whose prime manifestation is skeletal muscle inflammation. Juvenile dermatomyositis (JDM) is the most common of the juvenile IIM, with an incidence of about 1.9-4.1 per million children per year. 1 Besides the skeletal muscle inflammation, JDM is characterised by skin inflammation and manifests itself clinically as symmetric proximal muscle weakness and cutaneous symptoms such as papules over the knuckles (Gottron's papules), skin rashes, nail fold erythema, ulceration and calcinosis (deposition of subcutaneous or intramuscular calcium). JDM is a systemic disease, potentially involving other organ systems as well. If not adequately treated, the inflammation may cause muscular damage, leading to permanent muscle weakness and life-long disabilities, and skin atrophy. 2, 3 The prognosis of JDM is variable with about 24-40% of patients experiencing a monocyclic course, and the majority of patients (50-60%) showing a chronic disease pattern. The mortality rate of JDM is about 2-3%.
This clinical picture highlights that JDM is a disease with a significant medical, social and economic burden. 1, 4 Some studies suggest that early aggressive treatment improves the outcome for children with JDM, thereby alleviating this burden. 5 On the other hand, the treatment itself is associated with serious side effects, such as growth failure, pubertal delay and osteoporosis. As a consequence, it is good practice to administer as few drugs as possible, especially in paediatrics, in order to limit the negative effects on the normal physiology of the developing child. As such, the clinical challenge is to stratify patients according to their prognosis and adapt their treatment plans in concordance with their expected prognosis.
To answer the clinical question of interest, we need to identify clinical markers associated with disease activity and capable of predicting its evolution. Insight has been gained by the study of the various antibody patterns in the juvenile IIM 2, 3, 6 mainly to distinguish between JDM and the other subtypes of the juvenile IIM. Two previous studies have evaluated the potential of clinical variables to predict disease activity 1, 7 but these studies have the limitation of measuring disease activity as a binary outcome (active vs. non-active). Moreover, whereas Stringer et al. 7 analyse the time to remission, Ravelli et al. 1 evaluate disease activity cross-sectionally at approximately 7.7 years after disease onset.
In contrast, the aim of the current study is to identify variables associated with disease activity of JDM by modelling clinically relevant, continuous response variables over time using clinical markers and symptoms of the disease as covariates. Such a model could be used to inform physicians about features associated with disease activity, as well as guide clinicians in the management of the disease.
Data 2.1 Data collection
Data are available from a national longitudinal cohort study, in which children with definite or probable JDM according to Bohan and Peter criteria 8, 9 are enrolled across the UK. The study has been described previously. 4 Enrolment started in 2000 and is ongoing. Patients are enrolled at diagnosis, or as soon as they come to the attention of one of the participating centres, and are followed up every 3 months for 2 years and subsequently at least annually. Data collected concern disease manifestations, such as muscular involvement, skin disease and other organ involvement. Routine laboratory blood tests are also performed.
At each visit four outcome parameters 10 are measured as proxy of disease activity:
. Serum creatine kinase level (CK), a muscle enzyme which is released into the blood stream in increased amounts in case of muscular inflammation. The serum level of this enzyme is usually elevated in active JDM, but tends to be relatively low. 3 Its theoretical range is in (0,1) and values exceeding 150 U/L are considered pathological. 10 Many laboratories report a censored value of <20 U/L if the level is below the laboratory's detection limit. . Childhood myositis assessment scale (CMAS) which assesses muscular strength and endurance. 11 The CMAS consists of a series of little tasks, which the child is asked to perform, such as raising his/her head for at least 2 minutes while laying supine, raising to his/her feet from a sitting position and performing sit ups, with and without counterbalance. A predefined number of points is assigned based on the performance of the child and the total CMAS score is the sum over all tasks, ranging from 0 to 53, with a lower score indicating more active disease. Scores of at least 48 points are considered normal. 10 . Manual muscle testing of 8 muscle groups (MMT8), which consists in the assessment of muscle strength of 8 predefined muscle groups. Each muscle group is then assigned by the examiner a score ranging from 0 (equal to a complete loss of muscle contraction) to 10 (equal to full muscle strength). The total MMT8 is the sum over all muscle groups, thus ranging from 0 to 80, with a lower score indicating higher disease activity. A value of at least 78 points is considered normal.
10
. Physician's global assessment of disease activity (PGA), which is the physician's rating of disease activity, taking into account muscular disease, skin involvement and all other organ involvement. The PGA ranges from 0.0, indicating no disease activity, to 10.0, indicating maximal disease activity. The PGA should be at most 0.2 points to be considered normal. 10 Ethical approval of the study was obtained and all participants and their parents (as appropriate) provided informed consent. The study was conducted according to good clinical practice guidelines and the declaration of Helsinki.
Data cleaning
At the time of analysis, 4122 visits of 469 patients are available. Patients not fulfilling the inclusion criteria of having probable or definite JDM according to Bohan and Peter criteria are excluded, leaving 413 patients contributing 3881 visits. Missing data are imputed in the Bayesian model, except for missing data on history variables, because these are based on patient's recollection. This leads to the exclusion of 73 patients. Therefore, the final model includes 340 patients, contributing 2725 visits. Baseline characteristics of included and excluded patients are compared in Table 1 . As expected, due to the exclusion of visits with missing data, patients having contributed fewer visits are more likely to be excluded altogether from the study. This, in turn, is more likely to occur in patients enrolled later in the course of their disease, therefore presenting less disease activity at enrolment (Table 1) .
Of the 340 included subjects, five fully observed participants (i.e. no missing values in the dependent and independent variables for all visits) are randomly selected for the out of sample predictions and are therefore excluded from the training set.
The original dataset contains 83 covariates that can be used as predictor variables, including the time elapsed since diagnosis at the visit, disease signs and symptoms and treatment variables. The number of covariates is reduced by excluding those hardly containing any information. To this end, a pre-selection is made by fitting linear mixed effects models, using the package lme4 12 available in the R software. 13 More in details, for each covariate we fit four independent linear mixed models, one for each outcome, including also time from diagnosis and a random intercept for the time from diagnosis. We obtain a p-value for the covariate by employing a Wald t test and retain the smallest one among the four models. We then rank the covariates according to their most significant p-value and in such a way we select the 50% most significant predictors. All treatment variables and the time elapsed since diagnosis are included in the model, regardless of their performance in the linear mixed effects model, because of clinical interest. This procedure leaves 47 covariates in the model.
Model 3.1 Model specification
As discussed previously, the data consist of N ¼ 340 patients, each of them contributing multiple visits. For each patient i at visit j, a vector of four outcome variables is measured,
, where m i is the number of observations for the ith patient. Additionally, for each subject i at visit j, a vector of covariates X ij is available and t ij denotes the time elapsed since diagnosis. To account for the longitudinal nature of the study and for dependency between visits for the same patients, we introduce a subject-specific random effect for each of the response variables. We then link the response variables by assuming a joint model for the random effects.
The continuous outcome variables are transformed to ensure normality: we take a log-transformation for the CK levels, whereas we choose a square-root transformation for CMAS, MMT8 and PGA, as it is a well-known variance stabilising transformation that can deal with the presence of zeros in the data. For ease of notation, in Figure 1 . These variables are modelled using a Bayesian approach.
Let us first consider the outcome variable CK, which we assume normally distributed: 
Here, ðCKÞ is a mean effect common to all subjects, ðCKÞ is the vector of coefficients for the covariates X ij , ðCKÞ is the common effect for the time elapsed since diagnosis t ij ,
is a subject-specific random intercept, while
is a patient-specific random coefficient for the time elapsed since diagnosis. As mentioned above, some of the CK values (n ¼ 14, 0:5% of the observations) are below the laboratory's detection level and reported as <20 or <21 (depending on the laboratory). These instances are modelled as truncated values, by specifying this observation as right-truncated at 20 or 21.
Most patients reach disease remission after a certain period of time and a large number of non-pathological values for CMAS, MMT8 and PGA are observed. From Figure 1 , it is clear that these variables are not normally distributed, but they show an excess of non-pathological values. For these clinical outcomes we assume a mixture of a point mass at the most frequent value ( ffiffiffiffiffi 53 p for CMAS, ffiffiffiffiffi 80 p for MMT8 and 0 for PGA) and a truncated Normal distribution for the other observations. This strategy is similar to the hurdle model 14 as we recognise the possibility that the mechanism determining non-pathological values may differ from those that influence the distribution of pathological observations. We specify a probit regression to link the probability of observing a non-pathological value for subject i at visit j to the time elapsed since diagnosis. Moreover, we assume a linear regression model for the continuous part of the mixture. where is the Kronecker delta and the non-pathological values are:
Here, TNð, 2 Þ denotes a truncated Normal distribution with mean and variance 2 . The truncation limit changes depending on the outcome variable, but the idea is to truncate the normal distribution according to the range of possible values the response can assume (since they represent clinical scores) and the non-pathological value. As such, on the transformed scale, the distribution of CMAS is truncated on the interval ð0, ffiffiffiffiffi 53 p Þ, the distribution of MMT8 on ð0, ffiffiffiffiffi 80 p Þ and the distribution of PGA on the interval ð0, ffiffiffiffiffi 10 p Þ.
We assume a probit regression for the weights of the mixture:
where È is the cumulative distribution function of the standard Normal distribution and
As in the case of creatine kinase, ðkÞ and ðkÞ are the common intercept and regression coefficient, respectively, common to all subjects, while i is the patient specific random effect. We complete the model by specifying a linear regression model for the continuous component of the mixture (see equation (1)):
Note that we do not include an individual random effect for ðkÞ ij . The four disease outcomes are measured in the same patient at the same time and capture different aspects of the same biological entity, i.e. disease activity. As such, they are correlated, especially CMAS and MMT8. Therefore, it is important to account for these correlations in the model. Following Li et al., 15 we specify a multivariate Normal distribution on subject-specific random effects to take the inherent correlation of the longitudinal outcomes into account. This approach leads to a more efficient estimation of the model parameters. Hence, the four by-subject random intercepts for the outcome variables are modelled as follows:
where 0 is a four-dimensional vector of zeros and denotes the precision matrix.
Prior specification
The model is completed by specifying uninformative prior distributions on the remaining parameters. We use independent Normal(0, 1000) priors for the intercepts ðkÞ and ðkÞ , as well as for the regression coefficients ðkÞ and ðkÞ , with k 2 fCK, CMAS, MMT8, PGAg. We place a Normalð0, 2 Þ prior on the patient-specific random slope van Dijkhuizen et al.
We assume a Multivariate Normal prior as random effects distribution. We choose for computational reasons a conjugate Wishart prior for the precision matrix in equation (3) with degrees of freedom ¼ 6 and centering matrix S ¼ I Â Â 10, where I is the identity matrix of appropriate dimension. As such the prior mean is given by EðÞ ¼ 0:1I. 15 
Bayesian variable selection
To identify the most influential variables on disease progression and to obtain a sparser and more interpretable model, we perform Bayesian variable selection of the 47 covariates entered into the model (except for time from diagnosis), following the approach proposed by Kuo and Mallick. 16 See O'Hara and Sillanpa¨a¨1 7 for a review of Bayesian variable selection methods.
In
The Beta hyperprior induces sparsity as it places most of its mass on 0 or 1. The same indicator variable is used for all instances of each covariate in the model, so that the covariate would be included or not simultaneously in the models describing the four longitudinal outcomes, i.e. the mean of the CK model, and the linear parts of the CMAS, MMT8 and PGA models. The prior on the coefficients p is still a Normal distribution with mean 0 and common precision , to which we assign a Gamma distribution with parameters (0.001, 0.001), as described previously.
Results
Posterior inference is performed in the R software version 3.2.2 13 and JAGS, using the package rjags 18 as interface. We run the chain for 30,000 iterations with a burn-in of 5000 and 2000 adaptation iterations. We thin the chain every 10 iterations.
The goodness of fit of the model is assessed visually in six randomly selected patients, each having contributed at least 10 visits. Their observed values of CK, CMAS, MMT8 and PGA are plotted over time, together with the model fit and 95% credible intervals (CI). The plot for PGA is shown in Figure 2 , plots for CK, CMAS and MMT8 were similar. The plots show a good fit of the model to the data. In particular, fluctuating patterns over time are predicted well by the model. Some observed values in Figure 2 are outside the posterior 95% CI, however, this happens only for 1.8% of the observations. Moreover, to better understand the predictive ability of the model, we consider the posterior predictive probability of an observation falling beyond the cut off point for pathological values for each of the four longitudinal outcomes, as defined in literature (i.e. >150 for CK, <48 for CMAS, <78 for MMT8 and >0.2 for PGA; note that these cut off points are defined on the original measurement scale 10 ). These predictions concern pathological values and are, therefore, relevant from a clinical point of view.
In order to assess the predictive performance of the proposed model we employ the Brier statistic. 19 This statistic assesses the quality of predictions when the response variable is binary:
where o i is a binary observation, f i is its predicted probability and N is the number of observations in the sample. In our case, the response variable is continuous, so in order to apply this statistic we discretise the response variable. We are interested in predicting whether each clinical outcome is above or below the above-mentioned thresholds. Then, the predicted f ij is the predictive probability of obtaining values larger or smaller than the specified threshold for each patient i in the sample and visit j. Hence, the Brier statistic becomes:
where Y d ij is the ijth response discretised with respect to the critical threshold (equal to 1 if Y ij assumes pathological values and 0 otherwise), N is the number of patients and m i is the number of observations for individual i. The sum is taken over all the patients in the sample and the observation times. The Brier score assumes values between 0 and 1, with lower scores indicating a better performance. 20 We obtain Brier scores equal to 0.12, 0.12, 0.08 and 0.05 for CK, CMAS, MMT8 and PGA, respectively. Following Steyerberg et al., 20 we calculate rescaled Brier scores, which are normalised with respect to the maximum obtainable Brier score for a non-informative model based on the observed frequency of the outcomes. The scaled Brier score is very similar to Pearson's R 2 statistic (high values indicate a good predictive performance). In our analysis, we obtain 49%, 42%, 63% and 80% for CK, CMAS, MMT8 and PGA, respectively, indicating moderate to good performance of the model.
We also perform out of sample predictions on the four outcomes for five randomly selected, fully observed patients collectively contributing seven observations (Figure 3 ). Once again, the results show good accuracy, with the model's predictions being close to the observed values and almost always on the same side of the cut-off point discriminating pathological values from non-pathological values, as established in the literature (150 U/L for CK, 48 points for CMAS, 78 points for MMT8 and 0.2 points for PGA). 10 In only two cases involving CMAS, the observed value is below the cut-off point, indicating a pathological value, whereas the predicted value is above. However, on a closer inspection we notice that in both these cases the observed values are close to the cut-off point (46 and 47, respectively). The relatively wide CI reflect the uncertainty in the predictions, the estimation of the parameters, as well as in the imputation of missing values.
The posterior estimates of the regression coefficients of the time elapsed since diagnosis and the 46 covariates are reported in Figure 4 . The variability associated with the estimates is reasonable as shown by the CI. As expected, CMAS, MMT8 and PGA tend to normalise over time, whereas the CK level does not significantly change from the time from diagnosis. Various clinical signs and symptoms are associated with the four outcomes, most notably a range of manifestations of skin disease, such as periorbital rash, rash on the trunk, rash over large joints, nail fold changes and facial swelling. These parameters are not only associated with PGA, but also with the strictly muscular outcomes CK and CMAS, indicating that patients who are doing worse with respect to muscular disease activity, tend to have higher cutaneous disease activity as well. As expected, patients having myalgia (muscle pain) or dysphonia (altered voice pitch due to inflammation of the muscles of the vocal cords) have much worse disease activity. Of signs and symptoms present at diagnosis, only arthritis is associated with improved disease activity with regard to the CMAS and MMT8 at the follow up visits, probably reflecting a subset of patients with an overlap syndrome between JDM and juvenile idiopathic arthritis (JIA).
The methodology developed by Li et al. 15 for modelling multiple correlated outcomes is adopted, because of the prior belief that the four outcomes for JDM are correlated. The posterior distribution of the correlation between the by-subject random intercepts for the four outcomes supports this prior belief. The estimates are shown in Table 2 , evidencing a substantial correlation between ðCMASÞ i and ðMMT8Þ i (0.54, 95% CI 0.42-0.65), highlighting the appropriateness of the adopted methodology.
In Appendix A, we present four extensions of the proposed modelling strategy and compare their performance to the one of the model presented in the previous section. Appendix B contains the JAGS code used to fit the original model.
Discussion
The aim of this work is to jointly model four correlated longitudinal outcomes that measure disease activity in JDM, including clinical markers and symptoms as covariates. To the best of our knowledge, this is the first study to model disease activity in JDM, taking account of (i) longitudinal disease activity; (ii) continuous outcome measures; (iii) four different response variables, measured simultaneously, accounting for correlations among them; and (iv) the particular characteristics of the distribution of the outcome variables due to the fact that many patients attain disease remission at a certain time point. To achieve this, we propose a statistical approach based on the work of Li et al. 15 and specify a joint random effects distribution for the four outcomes (see equation (3)). Moreover, since most enrolled patients present disease remission at a certain point in time, normal (i.e. non-pathological) values are observed for CMAS, MMT8 and PGA for a large number of follow up visits. Therefore, we observe an excess of non-pathological values in the empirical distribution of these variables. To account for this peak in the empirical distribution, we adopt an approach similar to a hurdle model for CMAS, MMT8 and PGA. 14 Our results show that the proposed model leads to accurate prediction of the outcome variables, corresponding well to observed patterns in the data over time. Moreover, even though the CI of the predictions are often large, the variability associated with the estimates for the regression coefficients is reasonable, as shown by relatively narrow CI. Indeed, Li et al. 15 demonstrated that their methodology leads to a more efficient estimation of the model parameters compared to a strategy that considers each outcome individually. Moreover, the posterior distribution of shows evidence of correlation between the by-subject random intercepts, especially between those for CMAS and MMT8 ( ¼ 0.54, 95% CI 0.42-0.65, Table 2 ), indicating that those subjects with a higher CMAS tend to have a higher MMT8 as well. This corresponds to existing clinical knowledge.
Our analysis shows that disease activity tends to decrease over time, especially with respect to CMAS, MMT8 and PGA, whereas CK levels in general do not change significantly over time (the change in CK level is estimated to be e 0:031 ¼ 1:03 U/L per year follow up; Figure 4 ). This is consistent with the clinically observed fact that CK levels tend to be relatively low in patients with JDM. 3 In the described cohort, the median CK level at baseline, shortly after diagnosis, is 103 U/L (Table 1) , which is considered a normal value. 10 Nonetheless, patients with myalgia, dysphonia or haematuria, all signs of more severe (systemic) disease, present more elevated CK levels ( Figure 4) . Furthermore, we find that different cutaneous manifestations of the disease, most notably periorbital rash, rash on the trunk, rash over large joints, nail fold changes and facial swelling, are associated with disease activity, especially with PGA, which is the only clinical response taking cutaneous disease activity into account directly. However, some of these skin manifestations, such as periorbital rash and nail fold changes, are associated with the strictly muscular disease activity responses as well. These findings are in line with previous studies, even though based on a different methodology. 1, 7 While Ravelli et al. 1 found associations between disease activity and sex, age at onset and dysphonia/dysphagy at onset, this study does not replicate these results (although we find an association between dysphonia at the visit and all four outcome variables). These differences may be explained by differences in ethnic composition of the samples (a mix of European and Latin-American patients for Ravelli et al. 1 while this study recruits only UK patients) and methodology. Specifically, Ravelli et al. 1 analysed each outcome individually using logistic regression at a median of 7.7 years after disease onset, therefore discretising the response and not accounting for the development over time, while we propose joint modelling of the longitudinal outcome on their original scale. Furthermore, this analysis includes time-varying clinical markers and symptoms determined at each study visit, whereas Ravelli et al. 1 mainly considered baseline variables. It can be hypothesised that the association between current signs and symptoms and disease activity parameters overwhelms the associations between baseline parameters and disease activity at the study visits. Indeed, most baseline variables are not shown to be influential when we perform Bayesian variable selection (Figure 4) . This is probably due to the fact that we integrate in the model information from different sources and across time, allowing us to better explain variability in the responses.
Since we did not impute history variables, we have excluded visits with missing values for these variables. Owing to this procedure, 73 patients are excluded altogether from the study. From a probabilistic point of view, patients contributing less visits are less likely to have any visit with completely observed history variables. This, in turn, is more likely to happen in patients who are enrolled in the study not immediately at the time of diagnosis, but later during their course of disease. Consequently, they have lower disease activity at enrolment. These observations explain the differences between included and excluded patients (Table 1) . These patients represent a biased subset of the study, often contributing just a few visits, and we believe their exclusion is not problematic. Missing values in non-history variables are imputed in the Bayesian model, by assuming missingness at random and as a result we are able to retain a large number of patients and visits in the model.
In conclusion, the proposed methodology based on joint modelling of four correlated longitudinal measures of disease activity in JDM and exploiting a hurdle model approach, leads to a well-fitting model able to explain observed patterns over time, resulting in clinically meaningful inferences. Various clinical markers and symptoms of JDM are shown to be associated with disease activity. The clinical implications of these findings will be discussed in a clinical paper. 
